Dr. Huang received a Ph.D. in epidemiology from the University of North Carolina at Chapel Hill in 1998, with concentrations on gene-environment interactions and etiologic heterogeneity of breast cancer, defined by molecular markers. She completed two years of postdoctoral research in the Epidemiology Department at Glaxo Wellcome and joined NCI as a staff scientist in DCEG in 2000. Since joining NCI, Dr. Huang has received the NCI DCEG Award for Outstanding Research Paper by a Staff Scientist in 2003, the NIH Award of Merit in 2014, and the NCI DCEG Distinguished Scientific Service Award in 2018.
Dr. Huang provides scientific consultations for nationwide research on cancer etiology and early markers in the NCI Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial; she attends steering, review, and management meetings for the Trial and participates in cohort consortium and data pooling efforts. As a cancer epidemiologist, her studies focus on cancer risk related to genetic, epigenetic, and other molecular markers in DNA repair, metabolic, infection, and inflammation pathways, with primary interests in colorectal and prostate tumors.
To request an interview with NCI researchers, contact the NCI Office of Media Relations.
email@example.com | 240-760-6600